(KRK) Krka d. d - Ratings and Ratios
Cardiovascular, Antibiotics, Antidiabetics, Central Nervous System, Oncology
KRK EPS (Earnings per Share)
KRK Revenue
Description: KRK Krka d. d
Krka d.d., listed under the ticker symbol KRK, is a Slovenian pharmaceutical company. The companys stock has demonstrated a stable performance, reflecting its solid position within the pharmaceutical industry.
The pharmaceutical industry is driven by factors such as demographic changes, including an aging population and an increased prevalence of chronic diseases, as well as advancements in medical technology and research. Krka d.d.s performance is likely influenced by its ability to innovate and adapt to these trends, as well as its capacity to navigate regulatory environments across different markets.
Key Performance Indicators (KPIs) for Krka d.d. include its Return on Equity (RoE) of 17.85%, indicating a strong ability to generate profits from shareholder equity. The companys Price-to-Earnings (P/E) ratio of 14.87 suggests that it is reasonably valued compared to its earnings. The Market Capitalization of 26,120.25M PLN underscores its significant size and market presence.
Economic drivers for Krka d.d. include the overall demand for pharmaceuticals, government policies on healthcare and drug pricing, and the competitive landscape within the industry. The companys Beta of 0.493 indicates a relatively lower volatility compared to the market, suggesting a defensive position that could be attractive to risk-averse investors.
To further assess Krka d.d.s investment potential, it would be essential to examine its revenue growth, profit margins, and dividend yield, as well as its research and development pipeline to gauge its future growth prospects. The companys ability to maintain its market share and expand into new markets will be crucial in driving its long-term success.
KRK Stock Overview
| Market Cap in USD | 7,052m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception |
KRK Stock Ratings
| Growth Rating | 94.3% |
| Fundamental | 68.7% |
| Dividend Rating | 85.0% |
| Return 12m vs S&P 500 | 31.3% |
| Analyst Rating | - |
KRK Dividends
| Dividend Yield 12m | 4.61% |
| Yield on Cost 5y | 11.59% |
| Annual Growth 5y | 11.26% |
| Payout Consistency | 99.5% |
| Payout Ratio | 66.4% |
KRK Growth Ratios
| Growth Correlation 3m | 89.7% |
| Growth Correlation 12m | 97.4% |
| Growth Correlation 5y | 91.5% |
| CAGR 5y | 23.41% |
| CAGR/Max DD 5y | 0.76 |
| Sharpe Ratio 12m | -0.19 |
| Alpha | 45.40 |
| Beta | 0.188 |
| Volatility | 21.18% |
| Current Volume | 0.4k |
| Average Volume 20d | 0.1k |
| Stop Loss | 828.3 (-3%) |
| Signal | -1.64 |
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (410.3m TTM) > 0 and > 6% of Revenue (6% = 116.7m TTM) |
| FCFTA 0.12 (>2.0%) and ΔFCFTA 7.13pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 78.87% (prev 77.18%; Δ 1.70pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.15 (>3.0%) and CFO 470.8m > Net Income 410.3m (YES >=105%, WARN >=100%) |
| Net Debt (202.0m) to EBITDA (146.2m) ratio: 1.38 <= 3.0 (WARN <= 3.5) |
| Current Ratio 4.04 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (30.7m) change vs 12m ago -0.18% (target <= -2.0% for YES) |
| Gross Margin 57.48% (prev 55.99%; Δ 1.49pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 65.36% (prev 64.20%; Δ 1.16pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 239.3 (EBITDA TTM 146.2m / Interest Expense TTM 516.0k) >= 6 (WARN >= 3) |
Altman Z'' 9.63
| (A) 0.50 = (Total Current Assets 2.04b - Total Current Liabilities 505.0m) / Total Assets 3.10b |
| (B) 0.75 = Retained Earnings (Balance) 2.33b / Total Assets 3.10b |
| (C) 0.04 = EBIT TTM 123.5m / Avg Total Assets 2.98b |
| (D) 3.47 = Book Value of Equity 2.33b / Total Liabilities 669.6m |
| Total Rating: 9.63 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 68.70
| 1. Piotroski 7.50pt = 2.50 |
| 2. FCF Yield 5.74% = 2.87 |
| 3. FCF Margin 18.45% = 4.61 |
| 4. Debt/Equity 0.28 = 2.46 |
| 5. Debt/Ebitda 4.58 = -2.50 |
| 6. ROIC - WACC -1.48% = -1.85 |
| 7. RoE 17.85% = 1.49 |
| 8. Rev. Trend 67.93% = 3.40 |
| 9. Rev. CAGR 7.77% = 0.97 |
| 10. EPS Trend 89.83% = 2.25 |
| 11. EPS CAGR 94.39% = 2.50 |
What is the price of KRK shares?
Over the past week, the price has changed by +1.43%, over one month by -3.17%, over three months by +13.91% and over the past year by +53.58%.
Is Krka d. d a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of KRK is around 1033.23 PLN . This means that KRK is currently undervalued and has a potential upside of +20.99% (Margin of Safety).
Is KRK a buy, sell or hold?
What are the forecasts/targets for the KRK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 108.9 | -87.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 1126.6 | 31.9% |
KRK Fundamental Data Overview
Market Cap EUR = 6.05b (25.81b PLN * 0.2344 PLN.EUR)
CCE Cash And Equivalents = 467.6m EUR (Cash only, last quarter)
P/E Trailing = 14.82
P/S = 13.0852
P/B = 2.5335
Beta = 0.493
Revenue TTM = 1.95b EUR
EBIT TTM = 123.5m EUR
EBITDA TTM = 146.2m EUR
Long Term Debt = 164.6m EUR (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 505.0m EUR (from totalCurrentLiabilities, last quarter)
Debt = 669.6m EUR (Calculated: Short Term 505.0m + Long Term 164.6m)
Net Debt = 202.0m EUR (calculated as Total Debt 669.6m - CCE 467.6m)
Enterprise Value = 6.25b EUR (6.05b + Debt 669.6m - CCE 467.6m)
Interest Coverage Ratio = 239.3 (Ebit TTM 123.5m / Interest Expense TTM 516.0k)
FCF Yield = 5.74% (FCF TTM 359.0m / Enterprise Value 6.25b)
FCF Margin = 18.45% (FCF TTM 359.0m / Revenue TTM 1.95b)
Net Margin = 21.09% (Net Income TTM 410.3m / Revenue TTM 1.95b)
Gross Margin = 57.48% ((Revenue TTM 1.95b - Cost of Revenue TTM 827.2m) / Revenue TTM)
Tobins Q-Ratio = 2.69 (Enterprise Value 6.25b / Book Value Of Equity 2.33b)
Interest Expense / Debt = 0.02% (Interest Expense 158.0k / Debt 669.6m)
Taxrate = 15.00% (from yearly Tax Provision: 62.9m / 419.1m)
NOPAT = 105.0m (EBIT 123.5m * (1 - 15.00%))
Current Ratio = 4.04 (Total Current Assets 2.04b / Total Current Liabilities 505.0m)
Debt / Equity = 0.28 (Debt 669.6m / last Quarter total Stockholder Equity 2.41b)
Debt / EBITDA = 4.58 (Net Debt 202.0m / EBITDA 146.2m)
Debt / FCF = 1.87 (Debt 669.6m / FCF TTM 359.0m)
Total Stockholder Equity = 2.30b (last 4 quarters mean)
RoA = 13.25% (Net Income 410.3m, Total Assets 3.10b )
RoE = 17.85% (Net Income TTM 410.3m / Total Stockholder Equity 2.30b)
RoCE = 5.01% (Ebit 123.5m / (Equity 2.30b + L.T.Debt 164.6m))
RoIC = 4.57% (NOPAT 105.0m / Invested Capital 2.30b)
WACC = 6.04% (E(6.05b)/V(6.72b) * Re(6.71%)) + (D(669.6m)/V(6.72b) * Rd(0.02%) * (1-Tc(0.15)))
Shares Correlation 5-Years: -90.0 | Cagr: -0.32%
Discount Rate = 6.71% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 78.80% ; FCFE base≈266.4m ; Y1≈276.1m ; Y5≈314.6m
Fair Price DCF = 180.8 (DCF Value 5.53b / Shares Outstanding 30.6m; 5y FCF grow 3.76% → 3.0% )
Revenue Correlation: 67.93 | Revenue CAGR: 7.77%
Rev Growth-of-Growth: -0.73
EPS Correlation: 89.83 | EPS CAGR: 94.39%
EPS Growth-of-Growth: 84.29